Citations

Showing 10 of 108152 citations.

Heads Up: Our Definition of “Normal” Matters
Munis, James R. , Munis, James

Mayo Clinic

Anesthesia & Analgesia | June 20, 2019 | Volume: 129 | Issue: 3 | Pages: e108-e108

10.1213/ane.0000000000004283 | PMID 31425246 Get It

The American Board of Anesthesiology’s Standardized Oral Examination for Initial Board Certification
Harman, Ann E., Keegan, Mark T. , Dainer, Rupa J., McLoughlin, Thomas M, Fahy, Brenda G. , Macario, Alex, Sun, Huaping , Warner, David O. , Patterson, Andrew J., Rathmell, James P.

Mayo Clinic

Anesthesia & Analgesia | June 20, 2019 | Volume: 129 | Issue: 5 | Pages: 1394-1400

10.1213/ane.0000000000004263 | PMID 31219924 Get It

The American Board of Anesthesiology (ABA) has been administering an oral examination as part of its initial certification process since 1939. Among the 24 member boards of the American Board of Medical Specialties, 13 other boards also require passing an oral examination for physicians to become certified in their specialties. However, the methods used to develop, administer, and score these examinations have not been published. The purpose of this report is to describe the history and evolution of the anesthesiology Standardized Oral Examination, its current examination development and administration, the psychometric model and scoring, physician examiner training and auditing, and validity evidence. The many-facet Rasch model is the analytic method used to convert examiner ratings into scaled scores for candidates and takes into account how difficult grader examiners are and the difficulty of the examination tasks. Validity evidence of the oral examination includes that it measures aspects of clinical performance not accounted for by written certifying examinations, and that passing the oral examination is associated with a decreased risk of subsequent license actions against the anesthesiologist. Explaining the details of the Standardized Oral Examination provides transparency about this component of initial certification in anesthesiology.
PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD+ acute myeloid leukemia
Zhu, Ying‐Hui , Du, Juan , Dong, Haojie , Zhu, Lei , Wang, Hanying , Ding, Zonghui , Zhao, Dandan , Wang, Zhihao , Wu, Herman, Zhang, Han , Jiang, Wenjuan , Xu, Yang , Jin, Jian , Shen, Yudao , Perry, J. Jefferson P. , Zhao, Xinyang , Zhang, Bin , Liu, Songbai , Xue, Shengli , Shen, Binghui , Chen, Chun‐Wei , Chen, Jianjun , Khaled, Samer K. , Kuo, Ya‐Huei , Marcucci, Guido , Luo, Yun , Li, Ling , Chen, Chun-Wei , He, Xin , Lin, Yi‐Chun , Li, Min , Sun, Jie , Zhang, Lei , Zhang, Lianjun , Chen, Jianjun

Mayo Clinic

Blood | June 19, 2019 | Volume: 134 | Issue: 6 | Pages: 548-560

10.1182/blood.2019001282 | PMID 31217189 Get It

Abstract The presence of FMS-like receptor tyrosine kinase-3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukemia (AML) is associated with poor clinical outcome. FLT3 tyrosine kinase inhibitors (TKIs), although effective in kinase ablation, do not eliminate primitive FLT3-ITD+ leukemia cells, which are potential sources of relapse. Thus, understanding the mechanisms underlying FLT3-ITD+ AML cell persistence is essential to devise future AML therapies. Here, we show that expression of protein arginine methyltransferase 1 (PRMT1), the primary type I arginine methyltransferase, is increased significantly in AML cells relative to normal hematopoietic cells. Genome-wide analysis, coimmunoprecipitation assay, and PRMT1-knockout mouse studies indicate that PRMT1 preferentially cooperates with FLT3-ITD, contributing to AML maintenance. Genetic or pharmacological inhibition of PRMT1 markedly blocked FLT3-ITD+ AML cell maintenance. Mechanistically, PRMT1 catalyzed FLT3-ITD protein methylation at arginine 972/973, and PRMT1 promoted leukemia cell growth in an FLT3 methylation–dependent manner. Moreover, the effects of FLT3-ITD methylation in AML cells were partially due to cross talk with FLT3-ITD phosphorylation at tyrosine 969. Importantly, FLT3 methylation persisted in FLT3-ITD+ AML cells following kinase inhibition, indicating that methylation occurs independently of kinase activity. Finally, in patient-derived xenograft and murine AML models, combined administration of AC220 with a type I PRMT inhibitor (MS023) enhanced elimination of FLT3-ITD+ AML cells relative to AC220 treatment alone. Our study demonstrates that PRMT1-mediated FLT3 methylation promotes AML maintenance and suggests that combining PRMT1 inhibition with FLT3 TKI treatment could be a promising approach to eliminate FLT3-ITD+ AML cells.
Nontraditional Use of TEE to Evaluate Hepatic Vasculature and Guide Surgical Management in Orthotopic Liver Transplantation
Khurmi, Narjeet , Seman, Mitchell T. , Gaitan, Brantley, Rosenfeld, David M. , Giorgakis, Emmanouil , Hewitt, Winston R. , Mathur, Amit K. , Seman, Mitchell, Young, Scott , Rosenfeld, David, Hewitt, Winston, Mathur, Amit , Giorgakis, Emmanouil , Young, Scott W.

Mayo Clinic

Case Reports in Transplantation | June 19, 2019 | Volume: 2019 | Issue: No issue available | Pages: 1-6

10.1155/2019/5293069 | PMID 31321114 Get It

Intraoperative Transesophageal Echocardiography (TEE) during orthotopic liver transplant (OLT) is used to gather real-time information on cardiovascular function and intravascular volume status. We report a case where nonstandard TEE views were used to inspect the hepatic vasculature after allograft implantation. A 29-year-old male with secondary biliary cirrhosis with a MELD score of 20 underwent OLT using a liver from a 21-year-old brain-dead donor. Postreperfusion TEE, using the modified hepatic vein views, confirmed the presence of an inferior vena cava (IVC) suprahepatic anastomotic stenosis and hepatic vein and IVC thrombus resulting in hepatic venous outflow obstruction, allograft congestion, and hemodynamic instability. These nonstandard TEE images established the extent of suprahepatic caval outflow obstruction, in which intraoperative ultrasound was unable to definitively demonstrate. This guided real-time surgical decision-making in the postimplantation phase of the operation—ultimately leading to hepatic vein and IVC thrombectomy and revision of suprahepatic caval anastomosis.
The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials
DeLoughery, Emma P. , Puy, Cristina , McCarty, Owen J. T. , Shatzel, Joseph J. , Olson, Sven R.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | June 19, 2019 | Volume: 45 | Issue: 05 | Pages: 502-508

10.1055/s-0039-1692439 | PMID 31216587 Get It

AbstractAlthough anticoagulation without hemorrhage is a primary aim, this vision has remained as yet out of reach. Even despite the superior safety profile of the direct oral anticoagulants, hemorrhage remains a major risk of anticoagulation. Selective inhibition of the contact pathway of coagulation, specifically coagulation factor XI (FXI) and/or factor XII (FXII), has now substantial epidemiologic and preclinical data supporting the notion that these factors contribute to pathologic thrombosis and are yet primarily dispensable for in vivo hemostasis. In this way, targeting FXI and FXII may revolutionize the future anticoagulation landscape. Several drugs are under development for this purpose, including: ISIS 416858, a FXI antisense oligonucleotide which impairs hepatic synthesis of FXI; MAA868, a monoclonal antibody that binds the procoagulant enzymatic site of both zymogen and activated FXI (FXIa); BAY 1213790, a monoclonal antibody that binds the procoagulant enzymatic site of FXIa only; and AB023, a monoclonal antibody that inhibits activated FXII-mediated activation of FXI, along with two small molecules in clinical trials. Each of these drugs have demonstrated favorable safety profiles in their phases 1 and 2 studies to date, with preclinical data also supporting efficacy of abrogating thrombosis in various animal models. Other benefits of some of these drugs include once-monthly dosing and safety in patients with renal or hepatic impairment, while others offer quickly metabolized parenteral options, thus providing more convenient and widely available anticoagulation options. Though still far from the marketplace, drugs targeting FXI and FXII have the potential to usher in a new era of anticoagulation therapy.
Faculty Opinions recommendation of Intravenous dexmedetomidine for the treatment of shivering during Cesarean delivery under neuraxial anesthesia: a randomized-controlled trial.
Sviggum, Hans P.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | June 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.735464234.793561434 Get It

Impact of hospitals’ Referral Region racial and ethnic diversity on 30-day readmission rates of older adults
Hamadi, Hanadi , Moody, LaRee , Apatu, Emma , Vossos, Helene , Tafili, Aurora , Spaulding, Aaron , Spaulding, Aaron , Hamadi, Hanadi Y

Mayo Clinic

Journal of Community Hospital Internal Medicine Perspectives | June 19, 2019 | Volume: 9 | Issue: 3 | Pages: 181-188

10.1080/20009666.2019.1613882 | PMID 31258855 Get It

Coexistence of Progressive Supranuclear Palsy With Pontocerebellar Atrophy and Myotonic Dystrophy Type 1
Koga, Shunsuke , Ahlskog, J. Eric , DeTure, Michael , Baker, Matt , Roemer, Shanu F. , Rademakers, Rosa , Ross, Owen A. , Dickson, Dennis W. , DeTure, Michael A, Dickson, Dennis W , Koga, Shunsuke , Ross, Owen A , Konno, Takuya

Mayo Clinic

Journal of Neuropathology & Experimental Neurology | June 19, 2019 | Volume: 78 | Issue: 8 | Pages: 756-762

10.1093/jnen/nlz048 | PMID 31216016 Get It

AbstractProgressive supranuclear palsy with predominant cerebellar ataxia (PSP-C) has been reported as a rare clinical subtype, but the underlying pathology of its cerebellar ataxia remains unclear. Here, we report a patient with the coexistence of PSP with pontocerebellar atrophy and myotonic dystrophy type 1 (DM1). A 73-year-old man who was an asymptomatic carrier of DM1 (66 CTG repeats) started developing ataxic gait with multiple falls, visual blurring, double vision, and word finding difficulty at age 62 and was initially diagnosed with multiple system atrophy (MSA). Subsequently, the diagnosis was changed to PSP due to hypometric downward gaze, reduced blink frequency, symmetric bradykinesia, rigidity, and the absence of autonomic dysfunction. He eventually developed delayed grip opening with percussion myotonia at age 72. At autopsy, severe neuronal degeneration and astrogliosis in the pontocerebellar structures suggested MSA, but immunohistochemistry for α-synuclein did not reveal neuronal or glial cytoplasmic inclusions. Immunohistochemistry for phospho-tau and 4-repeat tau confirmed a neuropathological diagnosis of PSP with exceptionally numerous coiled bodies and threads in the pontine base and cerebellar white matter. This unusual distribution of 4-repeat tau pathology and neuronal degeneration with astrogliosis is a plausible clinicopathological substrate of PSP-C.
Heme oxygenase-2 protects against ischemic acute kidney injury: influence of age and sex
Nath, Karl A. , Grande, Joseph P. , Croatt, Anthony J., Ackerman, Allan W., Farrugia, Gianrico , Katušić, Zvonimir S. , Belcher, John D. , Vercellotti, Gregory M. , Grande, Joseph P , Farrugia, Gianrico , Garovic, Vesna D.

Mayo Clinic

American Journal of Physiology-Renal Physiology | June 19, 2019 | Volume: 317 | Issue: 3 | Pages: F695-F704

10.1152/ajprenal.00085.2019 | PMID 31215802 Get It

Heme oxygenase (HO) activity is exhibited by inducible (HO-1) and constitutive (HO-2) proteins. HO-1 protects against ischemic and nephrotoxic acute kidney injury (AKI). We have previously demonstrated that HO-2 protects against heme protein-induced AKI. The present study examined whether HO-2 is protective in ischemic AKI. Renal ischemia was imposed on young and aged HO-2+/+ and HO-2−/− mice. On days 1 and 2 after renal ischemia, there were no significant differences in renal function between young male HO-2+/+ and HO-2−/− mice, between young female HO-2+/+ and HO-2−/− mice, or between aged female HO-2+/+ and HO-2−/− mice. However, in aged male mice, HO-2 deficiency worsened renal function on days 1 and 2 after ischemic AKI, and, on day 2 after ischemia, such deficiency augmented upregulation of injury-related genes and worsened histological injury. Renal HO activity was markedly decreased in unstressed aged male HO-2−/− mice and remained so after ischemia, despite exaggerated HO-1 induction in HO-2−/− mice after ischemia. Such exacerbation of deficiency of HO-2 protein and HO activity may reflect phosphorylated STAT3, as activation of this proinflammatory transcription factor was accentuated early after ischemia in aged male HO-2−/− mice. This exacerbation may not reflect impaired induction of nephroprotectant genes, since the induction of HO-1, sirtuin 1, and β-catenin was accentuated in aged male HO-2−/− mice after ischemia. We conclude that aged male mice are hypersensitive to ischemic AKI and that HO-2 mitigates such sensitivity. We speculate that this protective effect of HO-2 may be mediated, at least in part, by suppression of phosphorylated STAT3-dependent signaling.
10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis
Vernat, S. Servagi, Khalifa, Jonathan , Sun, Xu-Shan, Kammerer, Emmanuel , Blais, E. , Pan, Jianji , Qiu, Hao , Bar‐Sela, Gil , Simon, Jean-Marc, Blais, Eivind , Sio, Terence Tai-Weng, Bar-Sela, Gil , Faivre, Jean Christophe , Sio, Terence T. , Simon, Jean-Marc, Salleron, Julia , Thariat, Juliette

Mayo Clinic

Cancers | June 19, 2019 | Volume: 11 | Issue: 6 | Pages: 849

10.3390/cancers11060849 | PMID 31248183 Get It

(1) Background: To assess the role of postoperative external beam radiotherapy (pEBRT) on locoregional failure (LRF) for patients with locally advanced high-risk non-anaplastic thyroid carcinoma (naTC) at primary event or relapse. (2) Methods: Between 1995 and 2015, postoperative naTC patients with a theoretical indication for EBRT were included based on criteria that were common to American-British-French current guidelines, i.e., pT3-4, pN+, gross or microscopic residual disease. Inverse probability of treatment weighting (IPTW) after multiple imputation was used to reduce selection biases. (3) Results: Of 254 naTC patients, 216 patients underwent pEBRT (106 de novo, 110 at relapse, median dose 60 Gy) and 38 underwent surgery only. pEBRT patients had more gross residual disease, a major prognostic factor (p = 0.027) but less perineural invasion (p = 0.008) or lymphovascular emboli (p = 0.009). pEBRT patients more frequently underwent radioiodine therapy (p = 0.026). The 10-year cumulative incidence of LRF was 56% (95% CI, 32–74%) in operated patients, and 23% (95% CI, 17–30%) in pEBRT patients. After IPTW method, pEBRT reduced the risk of LRF (hazard ratio 0.30; 95% CI [0.18–0.49], p < 0.001), but had no impact on OS. In the pEBRT group, non-Intensity Modulated RadioTherapy (IMRT) plans and interruption of the radiotherapy were associated with poorer survival, while extended versus limited field strategy and dose were not. (4) Conclusions: In naTC patients who have pT3-4, pN+ disease or R1-2 resection, pEBRT improved LRF. Limited-field IMRT is preferred.